[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"dissection\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:dissection":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,59,91],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":21,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":33,"overallStatus":46,"whyStopped":4,"lastUpdateSubmitDate":47,"lastUpdatePostDateStruct":48,"startDateStruct":51,"completionDateStruct":53,"leadSponsor":55,"locationsCount":58},"100566711","long-term-characterization-of-gore-tag-conformable-thoracic-stent-graft-with-active-control-system-performance-100566711",false,"NCT06658730","Long-term Characterization of GORE® TAG® Conformable Thoracic Stent Graft With ACTIVE CONTROL System Performance","TGR 23-02TA","Inclusion Criteria:\n\n1. Patient or legally authorized representative (LAR) provides written authorization and\u002For consent per institution and geographical requirements.\n2. Patient has been or is intended to be treated with an eligible registry device.\\*\n3. Patient is age ≥ 18 years at time of informed consent signature.\n\n   * The intent to treat a patient with a Gore product must be made prior to soliciting for possible registry participation. If pre-procedure consent is not feasible due to emergent situation, consent prior to the time of discharge for the index procedure is acceptable.\n\nExclusion Criteria:\n\n1. Patient who is, at the time of consent, unlikely to be available for standard of care (SOC) follow-up visits as defined by the site's guidelines and procedures.\n2. Patient with exclusion criteria required by local law.\n3. Patient is currently enrolled in or plans to enroll in any concurrent investigational drug and\u002For investigational device study\\* within 12 months of Together Registry enrollment. Subjects cannot be enrolled in another Together Registry module protocol.\n\n   * The term \"study\" does not apply to other observational registries or quality improvement projects. Collection of Registry Device performance from interventional studies may be permissible provided device application is not investigational and there are no novel requirements that alter follow-up conduct (i.e., protocol-mandated interventions).","ALL","18 Years",{"count":19,"type":20},1500,"ESTIMATED","10 Years","OBSERVATIONAL","An observational, prospective multi-regional post-market registry collecting mid- and long-term data to assess outcomes through ten years of follow-up for subjects treated with GORE® TAG® Conformable Thoracic Stent Graft with ACTIVE CONTROL System as a part of routine clinical practice. This post-market registry for the GORE® TAG® Conformable Thoracic Stent Graft with ACTIVE CONTROL System (CTAG w\u002FAC) is intended to demonstrate that thoracic endovascular aortic repair (TEVAR) for lesions of the descending thoracic aorta continues to be a suitable treatment option for appropriately selected patients.",[25,26,27,28,29,30,31,32],"Vascular Disease","Dissection","Dissection Aortic Aneurysm","Dissection of Aorta","Aneurysm Thoracic","Aneurysm Dissecting","Transection Aorta","Intramural Hematoma",[34,35,36,37,38,39,40,41,42,43,14,44,45],"Endovascular","CTAG","Post-market Registry","Observational","Multi-regional","Real world data","Together Registry","Gore Together Registry","Gore Together Aortic Registry","Conformable Thoracic Stent Graft","TGR23-02TA","GORE TAG","RECRUITING","2026-06-19",{"date":49,"type":50},"2026-06-23","ACTUAL",{"date":52,"type":50},"2025-06-19",{"date":54,"type":20},"2038-08",{"name":56,"class":57},"W.L.Gore & Associates","INDUSTRY",36,{"id":60,"slug":61,"hasResults":11,"nctId":62,"briefTitle":63,"officialTitle":64,"acronym":65,"eligibilityCriteria":66,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":67,"targetDuration":21,"studyType":22,"phases":4,"briefSummary":69,"conditions":70,"keywords":79,"overallStatus":46,"whyStopped":4,"lastUpdateSubmitDate":81,"lastUpdatePostDateStruct":82,"startDateStruct":84,"completionDateStruct":86,"leadSponsor":88,"locationsCount":90},"100404373","panther-study-of-terumo-aortic-knitted-and-woven-grafts-and-cardiovascular-patches-100404373","NCT04545502","PANTHER Study of Terumo Aortic Knitted and Woven Grafts, and Cardiovascular Patches","A Prospective and Retrospective, Multi-Centre, Post-Market, Non-Interventional Study of Terumo Aortic Knitted and Woven Grafts, and Cardiovascular Patches","PANTHER","Inclusion Criteria:\n\n* Patients must meet all of the following inclusion criteria in order to be eligible for inclusion in the study:\n\nAll Patients:\n\n* Patient meets the minimum age as per local regulations at time of consent\n* Patient requires treatment with study device(s) according to the IFU(s)\n* Patient is willing and able to comply with all SOC procedures and study visits\n* Patient or their legally authorised representative (LAR) has given written informed consent to participate in study, including consent to collect data retrospectively\n\n  * For prospective emergency patients, retrospective consent is permissible\n  * For retrospective patients who are deceased at time of enrollment, local EC regulations relating to consent process should be followed.\n\nRetrospective Patients only:\n\n* Patient has a minimum of 1 year post-operative follow-up data available, or complete data to death.\n* Patient implant date is no more than 5 years prior to study start date.\n\nExclusion Criteria:\n\n* Any patient who meets any of the following exclusion criteria will be excluded from participation in the study:\n\n  * Patient is unable or unwilling to comply with the SOC procedures or follow-up regime\n  * Patient is contraindicated per the device IFU\n  * Patient has any other medical, social or psychological problems that in the opinion of the investigator preclude them from receiving this treatment and the procedures and evaluations pre- and post-procedure",{"count":68,"type":20},2000,"The purpose of this registry is to collect safety and performance data on all commercially available Terumo Aortic knitted and woven grafts, and cardiovascular patches in standard clinical practice.\n\nData will be collected both retrospectively and prospectively.",[71,26,72,73,74,75,76,77,78],"Aneurysm","Aortic Root Aneurysm","Aortic Root Dissection","Carotid Artery Injuries","Aortic Arch","Bypass Extremity Graft","Occlusive Vascular Disease","Aortic Diseases",[80],"Vascular Surgery","2025-05-28",{"date":83,"type":50},"2025-06-03",{"date":85,"type":50},"2021-02-17",{"date":87,"type":20},"2037-01",{"name":89,"class":57},"Vascutek Ltd.",31,{"id":92,"slug":93,"hasResults":11,"nctId":94,"briefTitle":95,"officialTitle":96,"acronym":97,"eligibilityCriteria":98,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":99,"enrollmentInfo":100,"targetDuration":4,"studyType":102,"phases":103,"briefSummary":105,"conditions":106,"keywords":109,"overallStatus":46,"whyStopped":4,"lastUpdateSubmitDate":111,"lastUpdatePostDateStruct":112,"startDateStruct":114,"completionDateStruct":116,"leadSponsor":118,"locationsCount":120},"100557559","a-trail-of-sperstent-used-for-residual-lesions-of-femoropopliteal-arteries-100557559","NCT06539689","A Trail of Sperstent® Used for Residual Lesions of Femoropopliteal Arteries","A Prospective, Multicenter and Randomized Controlled Trial to Evaluate the Efficacy and Safety of Sperstent® Peripheral Spot Stent System Used for the Residual Lesions After Percutaneous Transluminal Angioplasty of Femoropopliteal Arteries","SURF","Inclusion Criteria:\n\n* Age 18-85 years old, male or female;\n* The target lesion is located in the superficial femoral artery or the proximal popliteal artery;\n* Peripheral arterial stenosis or occlusive disease with symptoms consistent with the Rutherford classification 2 to 5;\n* Estimated life expectancy \\>1 year;\n* Subject has been informed of and understands the nature of the study and provides signed informed consent to participate in the study.\n\nAngiographic Inclusion Criteria:\n\n* Stenosis rate ≥70% under DSA by visual estimate, or 100% occluded lesion with a total lesion length less than 150mm (by visual estimate);\n* Reference vessel diameter is between 3 mm and 7.5 mm, 50mm≤Total cumulative length of target lesions≤250mm; (In the case of bilimb lesions, a single target lesion with one limb meeting the protocol criteria is selected by the investigator; More than 2cm between lesions are considered as 2 lesions);\n* After PTA treatment by DCB, there exists residual lesions, such as the target lesion has over 30% residual DS and\u002For presence of at least one post-PTA dissection (Type A-F) (by visual estimate);\n* Patients with unobstructed inflow tract or successfully treated, visual residual stenosis ≤50%;\n* Angiography showed at least one outflow tract was unobstructed at the distal end (Stenosis degree ≤70% before intervention).\n\nExclusion Criteria:\n\n* Target vessel had undergone open surgery such as bypass surgery or the target lesion is in-stent restenosis;\n* Patients with serum creatinine \\>2.5mg\u002Fdl during screening or undergoing long-term hemodialysis or peritoneal dialysis;\n* Severe coagulation disorder;\n* Patients with major vascular-related diseases, including acute lower extremity ischemia, active disseminated intravascular coagulation, thromboangiitis obliterans, deep vein thrombosis, and aneurysms of therapeutic lateral vessels (deep femur, superficial femur, or popliteal artery);\n* A history of major organ failure or other serious illness (including severe coronary heart disease, severe cardiac insufficiency, severe neurosis, or mental illness); Have received or plan organ transplantation, severe gastrointestinal bleeding);\n* Myocardial infarction or symptomatic stroke occurred within 3 months prior to enrollment;\n* Thrombolysis of target vessel within 72 hours before surgery, did not completely dissolve the thrombus;\n* Systemic infection or uncontrolled infection within the target limb;\n* Known allergy to contrast agents, nickel or titanium (Nitinol), heparin, aspirin, clopidogrel, anesthetics;\n* Women who are pregnant or breast-feeding, or women of childbearing age who have family plans within 1 year;\n* Patients who are planning to have major lower limb amputations on the target side of the lesion;\n* Endovascular or surgical procedures are performed on the target limb within 30 days before or 30 days after surgery;\n* Participating in clinical trials of other medical devices or drugs;\n* The investigator considers the patient is not suitable for participation in the clinical trial.\n\nAngiographic Exclusion Criteria:\n\n* Failure of the guidewire to pass through the lesion；\n* During the procedure, the target lesions had received or were scheduled to receive volume reduction procedures such as cryogenic angioplasty, laser angioplasty, and percutaneous intracavity plaque gyrotomy；\n* The target lesion before stent implantation is thrombotic obliteration, which is not suitable for stent implantation；\n* The target lesions were severely calcified and could not fully predilate; Or grade 4 calcification；\n* Acute vascular occlusion or acute or subacute thrombosis in the target lesion；\n* Stent was implanted into the target vessel before enrollment.","85 Years",{"count":101,"type":20},240,"INTERVENTIONAL",[104],"NA","This is a prospective, multi-center, randomized trial designed to investigate the efficacy and safety of Sperstent® peripheral spot stent system versus Everflex® self-expanding peripheral stent system in the endovascular treatment of post-balloon angioplasty (post-PTA) residual lesions including stenoses and\u002For dissections in femoral and proximal popliteal arteries.",[107,108,26],"Peripheral Arterial Disease","Stenosis",[107,110],"Spot stent","2024-08-01",{"date":113,"type":50},"2024-08-06",{"date":115,"type":50},"2024-06-04",{"date":117,"type":20},"2026-12-31",{"name":119,"class":57},"FrontAce Scientific Co., Ltd",12]